People: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

63.98EUR
11:35am EDT
Price Change (% chg)

€0.31 (+0.49%)
Prev Close
€63.67
Open
€63.93
Day's High
€64.00
Day's Low
€63.52
Volume
421,572
Avg. Vol
482,972
52-wk High
€67.78
52-wk Low
€55.20

Search Stocks

Oschmann, Stefan 

Brief Biography

Dr. Stefan Oschmann, PhD, has been Member of the Executive Board, General Partner and Head of Pharmaceuticals at Merck KGaA since January 1, 2011. He is responsible for Europe, the United States (Pharmaceuticals), Canada, Latin and Central America, as well as Africa and Middle East. After earning a degree in Veterinary Medicine and a Doctorate from Ludwig-Maximilians-Universitaet Muenchen, he took on a position at the International Atomic Energy Agency IAEA. In 1989 he joined the American company Merck & Co. (outside North America: MSD – Merck Sharp & Dohme). Following various positions in Belgium, the Netherlands and Austria he was appointed Vice President of Central and Eastern Europe in 1998 and Vice President of Europe in 1999. Until 2005 he was also in charge of the German business of Merck & Co. In 2005 he moved to the headquarters of Merck & Co., taking on the role of Senior Vice President in charge of Worldwide Human Health Marketing. In 2006 he became Member of Senior Management and Corporate Officer, in charge of Merck & Co.’s business in Europe, the Middle East, Africa and Canada. As of 2009, Dr. Oschmann served as President of Emerging Markets for Merck & Co. Since January 10, 2011 he is Chairman of the Board at Merck Serono S.A.

Basic Compensation

Total Annual Compensation, EUR Long-Term Incentive Plans, EUR All Other, EUR Fiscal Year Total, EUR
4,553,000 -- -- 5,786,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Rolf Krebs

95,026

Karl-Ludwig Kley

7,311,000

Heiner Wilhelm

72,019

Kai Beckmann

4,951,000

Constantin Fest

--

Stefan Oschmann

5,786,000
As Of 30 Dec 2013
Search Stocks